Skip to content

Heading to ASCO in Chicago? Learn how we can help bringing cancer treatments to patients in Europe. Talk to our team.

Boys playing football

Get the free whitepaper: How early access programs & real-world data help Biotechs succeed

Andrew Cummins

By Andrew Cummins

Director of Expanded Access Programs

Your essential guide to early access programs and real-world data in Europe

Discover the key considerations, steps, and strategies needed to establish a successful expanded access program (EAP) in Europe.

 

What’s inside?

This whitepaper gives in-depth advice and guidance for biotechs on how to design and establish a successful EAP in Europe.

Learn more about:

  • When and why companies turn to EAPs and how you can ensure the success of your EAP
  • The importance of real-world data for rare and orphan medicines and how to collect it as part of an EAP
  • What to do if your company doesn’t already have a European presence

Authors:

This guide is derived from a comprehensive webinar featuring insights from three industry experts.

  • Andrew Cummins, Director of Expanded Access Programs at Sciensus
  • Mathieu Loiseau, Director of Rare Clinical Services at Sciensus
  • Sara Radenovic, Director of Managed Access Programs at GSK